ClinicalTrials.gg
CompletedNCT05722743Updated Nov 4, 2026Results posted

Person-Environment Fit for Persons With Dementia

An interventional study of Harmony and National Institute on Aging Program in Dementia Alzheimers and Alzheimer Disease, sponsored by Elizabeth K Rhodus. Completed at 1 site in United States. Open to participants aged 21 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Elizabeth K Rhodus · Not applicable, Interventional, and Health services research

How we know

Updated Nov 4, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
21 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
737th of 1,610
84 · median 73
Started
2023
with 114 others
No phase
610 of 1,941
131 open now
Registered
1,551st of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 737th largest by enrollment of the 1,610 interventional ones that give a count, is one of 115 that started in 2023, is one of 610 with no phase, and was the 1,551st registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 21 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This trial will assess feasibility of a non-pharmacological intervention for persons living with Alzheimer's disease and related dementias (ADRD) to improve behavioral and psychiatric symptoms of dementia and functional performance.

Using a two-arm, prospective randomized controlled trial, 38 dyads (person with ADRD and caregiver) will complete an 8-week telehealth occupational therapy intervention provided via Zoom with caregivers and persons with dementia or receive an active control with 8 telehealth sessions to discuss publicly available caregiver education with a non-clinical research assistant.

03

Conditions studied

  • Dementia Alzheimers
  • Alzheimer Disease

Keywords

  • Behavioral
  • Occupational therapy
  • Alzheimer's disease and related dementias
  • Telehealth
  • Caregiver
04

Who can participate

Ages eligible
21 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Participants with Dementia

  • Men or women aged 60-99, inclusive.
  • Living at home in the community with one primary caregiver.
  • Diagnosis or probably diagnosis of dementia (confirmed by Clinical Dementia Rating Scale score of 1.0+)
  • If on psychotropic medication, they are at a point where dosage and treatment are stabilized for the duration of the study.
  • Functional sensory abilities with or without aids (hearing, vision, smell, touch, taste)
  • Caregiver report of challenges related to behaviors within 4 weeks of study enrollment.
  • Caregiver willing to participate throughout duration of study.
  • Contact with University of Kentucky Alzheimer's Disease Research Center or Kentucky Neuroscience Institute medical provider within 12 months of study recruitment.

Inclusion Criteria: Caregiver for Participants with Dementia

  • Men or women aged 21-99, inclusive.
  • Willingness to participate in study and implement recommended data collection tools.
  • English speaking, able to read and write.
  • Ability to retrieve and send mail.

Exclusion Criteria: Participants with Dementia

  • Unstable medical conditions within one month prior to screening visit such as poorly controlled blood pressure, diabetes, current cancer diagnosis, or breathing problems, etc.
  • Wheelchair or bed bound.
  • Residence in skilled nursing facility or facility-based care.
  • Caregiver report of physically violent behaviors.
  • Initiation of antipsychotic medication within 4 weeks prior to screening or unpredictable use of such medications
  • Diagnosis of profound or total sensory altering disorders including macular degeneration, legal blindness, total deafness, severe peripheral neuropathy, anosmia.
  • Major depression in past 12 months ( criteria), major mental illness such as schizophrenia, bipolar disorder, personality disorders, or recent (in past 12 months) alcohol or substance abuse.
  • Major infection within 4 weeks prior to the Baseline Visit.

Exclusion Criteria: Caregiver for Participant with Dementia:

  • Diagnosis of mild cognitive impairment or dementia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Harmony

    Participants in this group will receive the Harmony intervention.

    Behavioral: Harmony

  • Active comparator
    National Institute on Aging Program

    Participants in this group will receive the National Institute on Aging education.

    Behavioral: National Institute on Aging Program

Interventions

  • BehavioralHarmony

    The Harmony intervention builds on prior successful foundations of dementia care interventions with a novel approach combining remote implementation, antecedent education, and home environment intervention. The intervention will teach caregivers how to 1) assess the home environment as an antecedent to behavior for the person with ADRD, and 2) design and implement individualized environmental modification through an environmental cueing approach to address the needs of the person with ADRD in a supportive environment.

  • BehavioralNational Institute on Aging Program

    Standard of care will address behaviors and psychiatric symptoms of dementia (BPSD) for persons with ADRD, as recommended by their medical provider. Caregivers will receive training regarding home safety via a home safety handout based on National Institutes on Aging "Home Safety and Alzheimer's Disease" webpage.

06

What researchers measure

Primary outcomes

  1. Change in Patient Performance as Measured by Canadian Occupational Performance Measure (COPM)

    Criterion-referenced interview of patient performance with caregiver The COPM is a reliable and validated measure of performance in primary daily activities (self-care, leisure, productivity) with dyad-caregiver rated of performance and satisfaction. Scores are determined on a likert scale of 1-10 with 1 being lowest and 10 indicating highest of the topic of the question.

    Time frame: Baseline to 13 Week Follow-Up

  2. Caregiver Satisfaction of Patient Performance [Feasibility]

    The primary outcome analysis is the feasibility of implementation as measured by caregiver satisfaction. The Canadian Occupational Performance Measure will measure caregiver satisfaction of patient performance, high scores indicate higher levels of satisfaction. Range 0-10.

    Time frame: Baseline to 13 Week Follow-Up

Secondary outcomes

  1. Zarit Caregiver Burden Scale

    22-item survey, caregiver rates self-perceived level of burden on 5-point Likert scale. The social context of the person with ADRD will be described through analysis of caregiver demographics and rate of caregiver burden measured. Higher scores indicate greater burden. Range of 0-88 points. A score of 17 or more was considered high burden.

    Time frame: Baseline to 13 Week Follow-Up

  2. Neuropsychiatric Inventory Questionnaire (NPI-Q)

    The NPI-Q is commonly used as an assessment of behavioral and psychiatric symptoms of dementia in older adults diagnosed with mild cognitive impairment or dementia, internationally, with high reliability and validity. Assessment includes 12 behavioral and psychiatric domains which are rated by caregiver as present or absent (yes/no). Caregivers further rate severity of present behavioral domains. The severity score is summed to yield a total as a measure of BPSD burden. Higher scores indicate higher levels of behavior symptom severity and/or distress. Range 0-36

    Time frame: Baseline to 13 Week Follow-Up

  3. Functional Behavior Profile (FBP)

    Criterion-referenced survey completed by caregiver. The FBP has been established as a reliable and valid measure of task performance, social interaction, and problem solving with adults with ADRD. The FBP consists of 27 items rated from 0 to 4, with higher scores indicating better performance. The total score ranges from 0 to 108. The FBP includes three subscales: Task Performance (0-36), Social Interaction (0-24) and Problem Solving (0-48). Subscale scores are summed to calculate the total FBP score.

    Time frame: Baseline to 13 Week Follow-Up

07

Results

Posted Nov 4, 2026

Participant flow

Participant flow — Overall Study
MilestoneHarmonyNational Institute on Aging Program
Started3838
Completed3432
Not completed46
Withdrew: Lost to follow-up42
Withdrew: Adverse event04

Outcome measures

PrimaryChange in Patient Performance as Measured by Canadian Occupational Performance Measure (COPM)

Criterion-referenced interview of patient performance with caregiver The COPM is a reliable and validated measure of performance in primary daily activities (self-care, leisure, productivity) with dyad-caregiver rated of performance and satisfaction. Scores are determined on a likert scale of 1-10 with 1 being lowest and 10 indicating highest of the topic of the question.

Time frame:
Baseline to 13 Week Follow-Up
Reported as:
Mean · score on a scale
Change in Patient Performance as Measured by Canadian Occupational Performance Measure (COPM)
score on a scaleHarmonyNational Institute on Aging Program
Change in Patient Performance as Measured by Canadian Occupational Performance Measure (COPM)1.14 ± 2.21-0.37 ± 2.3
PrimaryCaregiver Satisfaction of Patient Performance [Feasibility]

The primary outcome analysis is the feasibility of implementation as measured by caregiver satisfaction. The Canadian Occupational Performance Measure will measure caregiver satisfaction of patient performance, high scores indicate higher levels of satisfaction. Range 0-10.

Time frame:
Baseline to 13 Week Follow-Up
Reported as:
Mean · score on a scale
Caregiver Satisfaction of Patient Performance [Feasibility]
score on a scaleHarmonyNational Institute on Aging Program
Caregiver Satisfaction of Patient Performance [Feasibility]2.34 ± 2.760.72 ± 1.86
SecondaryZarit Caregiver Burden Scale

22-item survey, caregiver rates self-perceived level of burden on 5-point Likert scale. The social context of the person with ADRD will be described through analysis of caregiver demographics and rate of caregiver burden measured. Higher scores indicate greater burden. Range of 0-88 points. A score of 17 or more was considered high burden.

Time frame:
Baseline to 13 Week Follow-Up
Reported as:
Mean · score on a scale
Zarit Caregiver Burden Scale
score on a scaleHarmonyNational Institute on Aging Program
Zarit Caregiver Burden Scale-0.84 ± 8.54-5.29 ± 6.22
SecondaryNeuropsychiatric Inventory Questionnaire (NPI-Q)

The NPI-Q is commonly used as an assessment of behavioral and psychiatric symptoms of dementia in older adults diagnosed with mild cognitive impairment or dementia, internationally, with high reliability and validity. Assessment includes 12 behavioral and psychiatric domains which are rated by caregiver as present or absent (yes/no). Caregivers further rate severity of present behavioral domains. The severity score is summed to yield a total as a measure of BPSD burden. Higher scores indicate higher levels of behavior symptom severity and/or distress. Range 0-36

Time frame:
Baseline to 13 Week Follow-Up
Reported as:
Mean · score on a scale
Neuropsychiatric Inventory Questionnaire (NPI-Q)
score on a scaleHarmonyNational Institute on Aging Program
Neuropsychiatric Inventory Questionnaire (NPI-Q)-0.81 ± 1.690.38 ± 1.59
SecondaryFunctional Behavior Profile (FBP)

Criterion-referenced survey completed by caregiver. The FBP has been established as a reliable and valid measure of task performance, social interaction, and problem solving with adults with ADRD. The FBP consists of 27 items rated from 0 to 4, with higher scores indicating better performance. The total score ranges from 0 to 108. The FBP includes three subscales: Task Performance (0-36), Social Interaction (0-24) and Problem Solving (0-48). Subscale scores are summed to calculate the total FBP score.

Time frame:
Baseline to 13 Week Follow-Up
Reported as:
Mean · score on a scale
Functional Behavior Profile (FBP)
score on a scaleHarmonyNational Institute on Aging Program
Functional Behavior Profile (FBP)6.16 ± 10.66-1.23 ± 7.42

Adverse events

Collected over 13 Weeks (Initial baseline through the 4 week follow up). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Harmony0/38 (0%)0/38 (0%)9/38 (23.7%)
National Institute on Aging Program0/38 (0%)2/38 (5.3%)3/38 (7.9%)
Most frequent serious events
Most frequent serious events
EventHarmonyNational Institute on Aging Program
Transient Ischemic AttackNervous system disorders0/381/38
Psychiatric Change Resulting in HospitalizationPsychiatric disorders0/381/38
Most frequent other events
Most frequent other events
EventHarmonyNational Institute on Aging Program
FallInjury, poisoning and procedural complications9/381/38
Fungal Skin InfectionInfections and infestations0/381/38
Transient Ischemic AttackNervous system disorders0/381/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)HarmonyNational Institute on Aging ProgramTotal
ADRD77.53 ± 9.93079.61 ± 10.27977.93 ± 9.996
Caregivers66.83 ± 10.18360.47 ± 11.27163.15 ± 10.809
Sex: Female, Male
Sex: Female, Male(Participants)HarmonyNational Institute on Aging ProgramTotal
ADRD — Female151025
ADRD — Male4812
Caregivers — Female121729
Caregivers — Male729
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HarmonyNational Institute on Aging ProgramTotal
ADRD — Hispanic or Latino415
ADRD — Not Hispanic or Latino151732
ADRD — Unknown or Not Reported011
Caregivers — Hispanic or Latino011
Caregivers — Not Hispanic or Latino161733
Caregivers — Unknown or Not Reported314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HarmonyNational Institute on Aging ProgramTotal
ADRD — American Indian or Alaska Native000
ADRD — Asian000
ADRD — Native Hawaiian or Other Pacific Islander000
ADRD — Black or African American303
ADRD — White161834
ADRD — More than one race000
ADRD — Unknown or Not Reported011
Caregivers — American Indian or Alaska Native000
Caregivers — Asian000
Caregivers — Native Hawaiian or Other Pacific Islander000
Caregivers — Black or African American303
Caregivers — White161935
Caregivers — More than one race000
Caregivers — Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)HarmonyNational Institute on Aging ProgramTotal
United States383876
08

Study locations

1 site
  • University of Kentucky
    Lexington, Kentucky 40536, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Jun 2025, 24 months.

Results were first posted in Nov 2026, 1 year 4 months after primary completion.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 24 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2022
First posted
Feb 10, 2023
StartActual
Jun 14, 2023
Primary completionActual
Jun 20, 2025
CompletionActual
Jun 20, 2025
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Interventions
Changed Harmony at HOME→Harmony. Arm changed Harmony at HOME→Harmony
Nov 4, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedChange in patient performancePatient Performance as measuredMeasured by Canadian Occupational Performance Measure (COPM)Time frame: 13weeks (baseline, post-intervention, follow up) → Baseline to 13 Week Follow-Up
  • EditedCaregiver satisfactionSatisfaction of patient performancePatient Performance [Feasibility]Time frame: 13 weeks (baseline, post intervention, follow up) → Baseline to 13 Week Follow-Up
Nov 4, 2026
Secondary outcomes
3 time frame changed, 5 removed, 1 description edited
What changed in the outcomes
  • Time frameZarit Caregiver Burden Scale13 weeks (baseline, post intervention, follow up) → Baseline to 13 Week Follow-Up
  • Time frameNeuropsychiatric Inventory Questionnaire (NPI-Q)13 weeks (baseline, post intervention, follow up) → Baseline to 13 Week Follow-Up
  • Time frameFunctional Behavior Profile (FBP)13 weeks (baseline, post intervention, follow up) → Baseline to 13 Week Follow-Up
  • DescriptionFunctional Behavior Profile (FBP): how it is measured was reworded
  • Removedother outcomeHome Occupational Environment Assessment (HOEA)Time frame: 1 time (baseline)
  • Removedother outcomeAdult Sensory Profile (ASP)Time frame: 1 time (baseline)
  • Removedother outcomeClinical Dementia Rating Scale (CDR-SUM)Time frame: 1 time (baseline)
  • Removedother outcomeDigital Biomarker of psychophysiological response to environment: heart rate variabilityTime frame: Device worn by patient for 7 consecutive days
  • Removedother outcomeDigital Biomarker of psychophysiological response to environment: electrodermal activityTime frame: Device worn by patient for 7 consecutive days
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedChange in patient performancePatient Performance as measuredMeasured by Canadian Occupational Performance Measure (COPM)Time frame: 13weeks (baseline, post-intervention, follow up) → Baseline to 13 Week Follow-Up
    • EditedCaregiver satisfactionSatisfaction of patient performancePatient Performance [Feasibility]Time frame: 13 weeks (baseline, post intervention, follow up) → Baseline to 13 Week Follow-Up
    Secondary outcomes 3 time frame changed, 5 removed, 1 description edited
    What changed in the outcomes
    • Time frameZarit Caregiver Burden Scale13 weeks (baseline, post intervention, follow up) → Baseline to 13 Week Follow-Up
    • Time frameNeuropsychiatric Inventory Questionnaire (NPI-Q)13 weeks (baseline, post intervention, follow up) → Baseline to 13 Week Follow-Up
    • Time frameFunctional Behavior Profile (FBP)13 weeks (baseline, post intervention, follow up) → Baseline to 13 Week Follow-Up
    • DescriptionFunctional Behavior Profile (FBP): how it is measured was reworded
    • Removedother outcomeHome Occupational Environment Assessment (HOEA)Time frame: 1 time (baseline)
    • Removedother outcomeAdult Sensory Profile (ASP)Time frame: 1 time (baseline)
    • Removedother outcomeClinical Dementia Rating Scale (CDR-SUM)Time frame: 1 time (baseline)
    • Removedother outcomeDigital Biomarker of psychophysiological response to environment: heart rate variabilityTime frame: Device worn by patient for 7 consecutive days
    • Removedother outcomeDigital Biomarker of psychophysiological response to environment: electrodermal activityTime frame: Device worn by patient for 7 consecutive days
    Interventions Changed Harmony at HOME→Harmony. Arm changed Harmony at HOME→Harmony
    + 4 other changes: index terms, verification date, oversight details and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05722743
Lead sponsor
Elizabeth K Rhodus
Responsible party
Elizabeth K Rhodus (Assistant Professor, University of Kentucky) — Sponsor-investigator
First posted
Feb 10, 2023
Start date
Jun 14, 2023
Primary completion
Jun 20, 2025
Completion
Jun 20, 2025
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Elizabeth Rhodus, PhD
principal investigator · University of Kentucky

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion